Pancreas

Overview

The pancreas is a soft, lobulated retroperitoneal gland weighing 70–120 g, stretching from the C-loop of the duodenum to the splenic hilum. Its dual nature sets it apart from every other digestive organ: roughly 85% of its mass is exocrine acinar tissue dedicated to producing the full complement of digestive enzymes, while ~2% consists of the endocrine islets of Langerhans embedded throughout the parenchyma. The two compartments are developmentally distinct — arising from separate dorsal and ventral pancreatic buds that fuse around gestational week 7 — yet are tightly coupled in function through paracrine signalling and a unique portal microcirculation that lets islet hormones bathe acinar tissue at high local concentrations.

The exocrine pancreas is essential for digestion of all three macronutrient classes. Acinar cells synthesise and package proteases (trypsinogen, chymotrypsinogen, proelastase, procarboxypeptidases), lipases (lipase, co-lipase, phospholipase A₂), and amylase as inactive zymogens, preventing autodigestion. Ductal centroacinar cells secrete a high-volume bicarbonate-rich fluid (up to 113 mEq/L HCO₃⁻) driven by CFTR-mediated Cl⁻/HCO₃⁻ exchange, which neutralises gastric acid in the duodenum and creates the pH optimum (~pH 7–8) required for enzyme activity. Three neural-hormonal phases — cephalic (vagal ACh), gastric (gastrin, continued vagal), and intestinal (CCK, secretin) — coordinate secretory volume and enzyme composition with meal size and type.

The endocrine islets integrate multiple inputs — blood glucose, circulating amino acids, fatty acids, GIP and GLP-1 from enteroendocrine L/K cells, and autonomic innervation — to produce tightly regulated insulin and glucagon pulses. Glucose-stimulated insulin secretion (GSIS) from β cells operates through a metabolic trigger (GLUT2/glucokinase → ATP/ADP ratio) that closes KATP channels, depolarises the membrane, opens L-type Ca²⁺ channels, and triggers granule exocytosis; this pathway is the target of sulfonylureas. Glucagon from α cells rises during fasting to drive hepatic glycogenolysis and gluconeogenesis; δ-cell somatostatin provides local inhibitory feedback on both α and β cells.

Anatomy & Structure

Region / Component	Key Features
Head	Nestled in the C-loop of the duodenum; contains the main pancreatic duct (Wirsung) and accessory duct (Santorini); uncinate process projects posterior to superior mesenteric vessels; head drained by pancreaticoduodenal arteries
Neck	Short (~2 cm) isthmus anterior to portal/SMV confluence; critical surgical landmark in pancreaticoduodenectomy (Whipple procedure)
Body & Tail	Retroperitoneal crossing the spine at L1–L2; tail reaches the splenic hilum; tail contains highest density of islets; blood supply from splenic artery branches
Main Duct (Wirsung)	Runs entire length, joins common bile duct at ampulla of Vater; sphincter of Oddi regulates combined flow; normal diameter ≤3 mm; >5 mm suggests obstruction or chronic pancreatitis
Acinar cells	~85% of mass; pyramidal cells with basal rough ER and apical zymogen granules; secrete proteases, lipases, amylase, and nucleases as inactive zymogens; regulated by CCK (high enzyme output) and ACh
Centroacinar & Ductal cells	Line duct lumens; express CFTR and SLC26A6 anion exchangers; secrete HCO₃⁻-rich fluid (up to 1.5 L/day total); stimulated by secretin; CFTR mutations → cystic fibrosis-related exocrine insufficiency
Islets of Langerhans	~1 million scattered throughout parenchyma, ~150–300 µm diameter; highest density in tail; each islet has a unique portal microcirculation — β cells in core are perfused first, then α/δ cells; paracrine insulin → α cells inhibits glucagon; paracrine somatostatin → inhibits both
Islet Cell Types	β cells 60–80% (insulin + C-peptide + amylin); α cells 15–20% (glucagon); δ cells 5–10% (somatostatin); PP cells (pancreatic polypeptide, head/uncinate dominant); ε cells <1% (ghrelin)

Function

The core functional outputs of the pancreas are macronutrient digestion (exocrine) and blood glucose homeostasis (endocrine). These two systems are coordinated during meals so that enzyme secretion and insulin release rise together in proportion to nutrient load.

GLUCOSE-STIMULATED INSULIN SECRETION (GSIS) Blood glucose ↑ (>5 mmol/L) → GLUT2 transports glucose into β cell (Km ~20 mmol/L; senses hyperglycaemia) → Glucokinase (hexokinase IV) phosphorylates → glucose-6-phosphate → Glycolysis + TCA → ↑ ATP/ADP ratio ↓ → KATP channel closes (SUR1/Kir6.2 complex) → Membrane depolarisation (−70 mV → −20 mV) → L-type voltage-gated Ca²⁺ channel opens → [Ca²⁺]i ↑ triggers insulin granule exocytosis Amplification signals GLP-1/GIP → Gs → cAMP → PKA + Epac2 → augment Ca²⁺-triggered exocytosis Amino acids (Arg, Leu) → depolarise β cell independently of glucose Vagal ACh (M3) → Gq → IP3/DAG → PKC → further amplification Sulfonylurea target: KATP (SUR1) → forced closure → insulin release independent of glucose

Exocrine — Three-Phase Secretion

Cephalic phase (20–25%): Sight/smell/taste of food → vagal ACh → acinar enzyme output; modest bicarbonate
Gastric phase (5–10%): Gastric distension + gastrin → sustained low-level secretion
Intestinal phase (60–70%): Chyme enters duodenum; fatty acids + protein → CCK from I cells → high enzyme secretion; acid + fatty acids → secretin from S cells → high bicarbonate (up to 113 mEq/L); enzyme:bicarbonate ratio inversely regulated by CCK:secretin balance

Zymogen Activation Cascade

Zymogens secreted to prevent autodigestion: trypsinogen, chymotrypsinogen, proelastase, procarboxypeptidases
Enterokinase (brush border of duodenum) cleaves trypsinogen → trypsin (master activator)
Trypsin cleaves all other zymogens: chymotrypsinogen → chymotrypsin; proelastase → elastase; procarboxypeptidases → carboxypeptidases
Pancreatic trypsin inhibitor (SPINK1) provides safety valve against premature activation in acinar cells
Lipase + colipase cleave triglycerides → 2-monoglyceride + fatty acids (bile needed for emulsification)

Glucagon & Counter-Regulation

α cells secrete glucagon when blood glucose <4 mmol/L, during amino acid loads, and under sympathetic drive
Glucagon → hepatic glucagon receptor → Gs/cAMP/PKA → glycogenolysis + gluconeogenesis → hepatic glucose output
Also lipolysis in adipocytes → FFA release → ketogenesis in fasting
Paracrine inhibition: insulin (from β cells via portal circulation within islet) suppresses glucagon; loss of intra-islet insulin in T1DM → unopposed glucagon → DKA risk
δ cells secrete somatostatin (SS-14 in islets) in response to both high glucose and high glucagon → tonic brake on both α and β cell secretion

Incretin Amplification

GLP-1 (L cells, distal small bowel) and GIP (K cells, duodenum/jejunum) are released by fat/protein/glucose in the intestinal lumen
Both bind Gs-coupled receptors on β cells → ↑ cAMP → augment GSIS (incretin effect: ~50–70% of postprandial insulin response)
GLP-1 also suppresses glucagon, slows gastric emptying, and enhances satiety
GLP-1R agonists (semaglutide, liraglutide) exploit this axis; DPP-4 inhibitors prevent GLP-1/GIP degradation (t½ ~2 min endogenous)
Incretin effect is severely blunted in T2DM despite intact GIP/GLP-1 secretion — GIP receptor downregulation implicated

Pathology

Pancreatic Ductal Adenocarcinoma (PDAC)

Most common pancreatic malignancy (~85% of cases); arises from ductal epithelium. Near-universal driver mutations: KRAS >90% (G12D/G12V/G12R), CDKN2A ~90%, TP53 ~70%, SMAD4 ~55%. Characterised by dense desmoplastic stroma that excludes immune cells and impairs drug delivery. Typically presents late — jaundice (head lesion), weight loss, back pain. Median survival 6–12 months without curative resection; only ~20% are resectable at diagnosis; 5-year survival ~12% overall. Surgical option: Whipple procedure (pancreaticoduodenectomy) or distal pancreatectomy. Gemcitabine ± nab-paclitaxel or FOLFIRINOX for advanced disease.

Type 1 Diabetes Mellitus (T1DM)

T-cell-mediated autoimmune destruction of β cells; HLA-DR3/DR4-DQ8 haplotypes confer highest risk. Autoantigens include GAD65, IA-2 (ICA512), ZnT8, and insulin. Insulitis precedes clinical onset by years; patients present with DKA or symptomatic hyperglycaemia once ~70–80% of β-cell mass is destroyed. Absolute insulin deficiency + unopposed glucagon → lipolysis → ketoacidosis. Management: multiple daily injections or continuous subcutaneous insulin infusion (CSII); closed-loop systems (artificial pancreas). Anti-CD3 (teplizumab) delays onset in high-risk first-degree relatives (stage 2 T1DM).

Type 2 Diabetes Mellitus (T2DM)

Combination of peripheral insulin resistance (muscle, liver, adipose) and progressive β-cell loss (~40–60% reduction at diagnosis). β-cell failure is multifactorial: glucotoxicity, lipotoxicity, amyloid deposition (IAPP/amylin), endoplasmic reticulum stress, and mitochondrial dysfunction. Glucagon hypersecretion persists despite hyperglycaemia (the "missing brake"). Incretin effect is blunted. Pharmacotherapy: metformin (↓ hepatic glucose output), GLP-1 agonists (↑ insulin, ↓ glucagon, weight loss), SGLT2 inhibitors (renal glucose excretion, cardio/renoprotection), sulfonylureas/glinides (KATP closure), and ultimately insulin.

Acute Pancreatitis

Premature intracellular activation of zymogens within acinar cells triggers autodigestion and a SIRS-like systemic inflammatory cascade. Leading causes: gallstones (40–70%, biliary obstruction at ampulla of Vater), alcohol (>5 drinks/day × years, 25–35%), hypertriglyceridaemia, medications, ERCP trauma. Severity by revised Atlanta criteria: mild (no organ failure, no local complications) → moderately severe (transient organ failure <48h or local complications) → severe (persistent organ failure ≥48h). Necrosis + infection (infected necrotising pancreatitis) carries 20–30% mortality. CT severity index (Balthazar/CTSI) guides management. Treatment: aggressive IV hydration, pain control, early enteral nutrition, antibiotic only for infected necrosis.

Chronic Pancreatitis

Irreversible fibroinflammatory destruction of pancreatic parenchyma resulting in exocrine insufficiency (steatorrhoea, fat-soluble vitamin malabsorption) and endocrine insufficiency (pancreatogenic/type 3c diabetes). Alcohol + smoking is the most common aetiology; hereditary chronic pancreatitis from PRSS1 (cationic trypsinogen), SPINK1, or CFTR mutations in younger patients. Pathognomonic: parenchymal calcifications on CT (calcium carbonate stones in ducts). Pain management is the greatest clinical challenge (central sensitisation); endoscopic/surgical drainage for large duct disease; enzyme replacement therapy (PERT) for EPI; monitoring for PDAC (10× increased lifetime risk).

Pancreatic Neuroendocrine Tumours (PNETs)

Arise from islet cells; most (~65%) are non-functional (discovered incidentally or from mass effect). Functional PNETs cause dramatic clinical syndromes: Insulinoma (most common functional PNET, ~90% benign, Whipple's triad: symptoms with glucose <2.2 mmol/L, relief with glucose); Gastrinoma (Zollinger-Ellison syndrome: refractory peptic ulcers, diarrhoea; 50–60% malignant; 25% in MEN1); Glucagonoma (necrolytic migratory erythema, diabetes, hypoaminoacidaemia); VIPoma (WDHA: watery diarrhoea, hypokalaemia, achlorhydria); Somatostatinoma (diabetes, gallstones, steatorrhoea). Grade 1–3 by Ki-67; somatostatin receptor scintigraphy (Ga-68 DOTATATE PET) is the imaging modality of choice. Treatment: somatostatin analogues (octreotide/lanreotide), PRRT, everolimus/sunitinib, or surgery.

Connections

part-ofDigestive System modulatesDuodenum connects-toLiver connects-toCardiovascular System connects-toIntestinal Epithelium containsInsulin (β cells) modulatesBlood Glucose modulated-byImmune System (T1DM) damagesRenal System (diabetic nephropathy) treated-byGLP-1 Agonists treated-byInsulin Therapy treated-bySGLT2 Inhibitors